Insitro, an AI-driven biotechnology company, is partnering with Eli Lilly to develop novel treatments for metabolic diseases. The collaboration aims to leverage Insitro's machine learning tools to identify new drug targets and advance experimental genetic medicines, potentially leading to clinical trials as early as 2026. This partnership inverts the traditional biotech-pharma model, with Insitro leading clinical development.
Identifying Novel Targets with AI
Insitro has identified two genes believed to be linked to metabolic diseases, including fatty liver diseases, using its machine learning platform. These targets represent a novel approach to addressing metabolic dysfunction, an area where genetic understanding has been limited due to diagnostic challenges. "These are novel targets with strong genetic support," said Daphne Koller, CEO of Insitro, highlighting the potential of these discoveries.
Leveraging Lilly's GalNAc Technology
To deliver gene-silencing siRNA molecules to liver cells, Insitro will have the option to license Lilly's GalNAc conjugate technology. This targeted delivery system is crucial for the effectiveness of siRNA therapeutics, ensuring that the drug reaches the intended cells and minimizes off-target effects.
Collaborative Development and Clinical Trials
Under the agreement, Insitro will also collaborate with Lilly to develop an antibody against a secreted target. Insitro will be responsible for running the clinical trials for all three programs. Lilly will provide milestone and royalty payments upon successful drug development and commercialization.
AI in Drug Discovery
Daphne Koller, a prominent figure in the intersection of AI and biology, has raised $643 million since 2018 to advance Insitro's AI-powered drug discovery platform. Insitro has recently published research demonstrating its ability to predict genetic details of cancer cells from biopsies, develop new screening methods for ALS drug discovery, and identify genetic loci linked to metabolic dysfunction-associated steatotic liver disease (MASLD).
Addressing Fatty Liver Disease
Insitro's work on fatty liver disease is among its most advanced programs. The company has developed methods to predict liver fat content using AI analysis of bone density scans and blood molecules from UK Biobank participants. This approach has enabled the discovery of new genetic links that were previously difficult to identify due to limited data.
Strategic Implications
This partnership signifies a strategic shift in the pharmaceutical industry, where AI-driven drug discovery is gaining prominence. By combining Insitro's AI capabilities with Lilly's expertise in drug development and delivery, the collaboration aims to accelerate the development of innovative treatments for metabolic diseases.
